Zydus Lifesciences Ltd

Zydus Lifesciences Earnings Call: Key Takeaways

Zydus delivered a record-breaking FY26 with 17% revenue growth and peak EBITDA margins of 31.2%, significantly exceeding internal expectations.

Zydus Lifesciences Results Update

Zydus Lifesciences reported FY26 revenues of ₹27,148 Crore and approved a ₹1,100 Crore share buyback. Strong performance across segments supports the multi-year growth outlook.

Value

₹1,100 Cr

Zydus Lifesciences Earnings Call: Key Takeaways

Zydus Lifesciences reported strong FY26 performance with 16% YoY revenue growth and EBITDA margins expanding to 31.2%. Strategic focus remains on US specialty/rare diseases and domestic chronic therapy leadership.

Zydus Lifesciences Dividend

Zydus Lifesciences declared a final dividend of Re. 1 per share for FY2026. The record date is July 24, 2026, pending shareholder approval.

Zydus Lifesciences Management Change

Zydus Lifesciences re-appointed Dr. Sharvil P. Patel as Managing Director and appointed Mr. Kulin S. Lalbhai as Independent Director. Both roles carry five-year terms.

Execution

5 years

Zydus Lifesciences Merger & Restructuring Worth ₹1,100 Cr

Zydus Lifesciences approved a ₹1,100 Crore share buyback at ₹1,150 per share. The tender offer targets 95,65,217 shares, representing a significant premium to market price.

Value

₹1,100 Cr

Zydus Lifesciences Q4 FY26 Results: Net Profit ₹1,272 Cr, Up 8.7% YoY

Zydus Lifesciences Ltd reported revenue from operations of ₹7,587 Cr (+16.2% YoY) and net profit of ₹1,272 Cr (+8.7% YoY) for Q4 FY26.

Key figure

Net profit ₹1,272 Cr · +8.7% YoY

Zydus Lifesciences Financial Results

Zydus Lifesciences reported consolidated net profit of ₹5,040 Crore for FY26. The board recommended a 100% final dividend of ₹1 per equity share.

Zydus Lifesciences Acquisition Worth ₹1,581 Cr

Zydus Lifesciences is acquiring Assertio Holdings for approximately ₹1580.8 Crore in cash. The deal establishes an immediate U.S. specialty oncology commercial footprint and infrastructure.

Value

₹1,581 Cr

Execution

Financial year 2026-27

Zydus Lifesciences Legal & Regulatory

Zydus Lifesciences received an appeal order upholding a ₹1.18 Crore GST demand and penalty. The company intends to file a second appeal before GSTAT.

Value

₹1.18 Cr

Zydus Lifesciences Board Meeting Date

Zydus Lifesciences will hold a board meeting on May 19, 2026, to consider a share buyback proposal. The trading window remains closed until May 21.

Zydus Lifesciences Management Change

Mr. Apurva S. Diwanji ceased to be an Independent Director at Zydus Lifesciences following his tenure completion. The change was effective from May 12, 2026.

Zydus Lifesciences Board Meeting Date

Zydus Lifesciences scheduled a board meeting on May 19, 2026, to approve audited FY26 results and recommend a final dividend. Trading window remains closed until May 21.

Zydus Lifesciences Business Update

Zydus Lifesciences Limited announced the conclusion of a USFDA GMP surveillance inspection at its Ahmedabad Biologics Injectable plant. The inspection ended with seven observations and no data integrity issues. The company intends to work closely with the regulator to address these findings expeditiously.

Zydus Lifesciences Legal & Regulatory

Zydus Lifesciences' subsidiary, Zydus VTEC Limited, received a GST demand and penalty order totaling ₹1.80 Crore for the period September 2020 to March 2023. The issue pertains to alleged inadmissible Input Tax Credit. The company intends to appeal the order and states there is no material financial impact.

Value

₹1.80 Cr

Zydus Lifesciences Acquisition Worth ₹7.79 Cr

Zydus Lifesciences' subsidiary, Amplitude SAS, has acquired a 100% stake in French medical equipment distributor FBC Medical for ₹7.79 Crore. The acquisition aims to internalize commercial capabilities and reduce long-term distribution costs in France. The transaction was completed on April 30, 2026.

Value

₹7.79 Cr

Zydus Lifesciences Acquisition Worth ₹4.01 Cr

Zydus Lifesciences' step-down subsidiary, Amplitude SAS, completed the 100% acquisition of French medical equipment distributor Aptitude Orthopedie for ₹4.01 Crore. The move internalizes commercial capabilities in France to reduce long-term selling costs and eliminate third-party commission fees.

Value

₹4.01 Cr

Zydus Lifesciences Acquisition Worth ₹7.77 Cr

Zydus Lifesciences Limited's indirect subsidiary, Amplitude SAS, acquired 100% of French medical equipment distributor FBC Medical for Euro 700,000 (₹7.77 Crore). The acquisition, completed on April 30, 2026, aims to internalize commercial capabilities and reduce long-term distribution costs in France.

Value

₹7.77 Cr

Zydus Lifesciences Acquisition Worth ₹3.99 Cr

Zydus Lifesciences Limited, through its subsidiary Amplitude SAS, acquired 100% of French medical equipment distributor Aptitude Orthopedie for approximately ₹3.99 Crore. The acquisition aims to internalize commercial capabilities and reduce long-term distribution costs.

Value

₹3.99 Cr

Zydus Lifesciences Merger & Restructuring

Zydus Lifesciences Limited, through its subsidiary Zydus Worldwide DMCC, incorporated a new wholly owned subsidiary named Zara Merger SUB Inc. in the USA on April 24, 2026. The new entity belongs to the pharmaceutical industry. There was no cash consideration for the incorporation.

Zydus Lifesciences Merger & Restructuring

Zydus Lifesciences incorporated a new wholly owned subsidiary, Zara Merger SUB Inc., in the United States on April 24, 2026. The entity is part of an internal group restructuring within the pharmaceutical industry. The subsidiary has not yet commenced business operations and currently reports nil turnover.

Zydus Lifesciences Regulatory Approval

Zydus Lifesciences received DCGI approval to initiate Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate. Two trials involving 651 and 390 patients will evaluate efficacy against P. falciparum and P. vivax malaria in India. This marks a significant milestone in developing alternatives to current artemisinin-based therapies facing resistance.

Zydus Lifesciences Regulatory Approval

Zydus Lifesciences Limited received the Establishment Inspection Report (EIR) and approval from the USFDA for its oncology injectable facility in SEZ1, Ahmedabad. The approval follows a Pre-Approval Inspection conducted in November 2025 for a new isolator injectable line. This regulatory milestone clears the path for commercial manufacturing at the site.

Zydus Lifesciences Legal & Regulatory

Zydus Lifesciences' subsidiary, GRPPL, received an appellate order dropping a previously imposed GST penalty of ₹0.17 Crore (Rs. 1.66 million) for FY 2018-19. The Office of Commissioner (Appeals) Ahmedabad set aside the demand, resulting in no material impact on the company's financials or operations.

Value

₹0.17 Cr

Zydus Lifesciences Other Announcement

Zydus Lifesciences Limited has been assigned an overall ESG rating of 68 by ESGRAIL, an improvement from last year's 66. The rating was prepared independently based on publicly available information. This update reflects the company's ongoing commitment to environmental, social, and governance standards.

Zydus Lifesciences Regulatory Approval

Zydus Lifesciences received final USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), used for type 2 diabetes. The drug had annual US sales of approximately ₹94,860 Crore. Zydus is eligible for 180 days of shared generic exclusivity, with manufacturing based in Ahmedabad SEZ.

Value

₹94,860 Cr

Execution

180 days of shared exclusivity

Zydus Lifesciences Legal & Regulatory

Zydus Lifesciences received a favorable order from the GST Adjudication Authority, Gandhinagar, dropping a tax demand of ₹4.18 Crore for FY 2019-20. The company noted the event is not material under SEBI regulations and was disclosed as a good governance practice.

Value

₹4.18 Cr

Zydus Lifesciences Legal & Regulatory

Zydus Lifesciences Limited received a favourable order from the GST Adjudication Authority in Gandhinagar. The order dropped a GST demand of ₹4.18 Crore (Rs. 41.77 million) for the financial year 2019-20. This positive regulatory outcome reduces the company's potential tax liabilities.

Value

₹4.18 Cr